E-Cadherin thoughts

Options
Anonymous
Anonymous Member Posts: 1,376
edited November 2019 in IDC (Invasive Ductal Carcinoma)
E-Cadherin thoughts
· Share on FacebookShare on Twitter

Comments

  • Hv2Cutedimples
    Hv2Cutedimples Member Posts: 7
    edited June 2019

    I just got the full path report back from the core needle biopsy. I am 95% Er and PR positive. I have ki67 score of 10%. I have loss of e-Cadherin cells. So my concern is the last part. I am worried. And does having a higher ER and PR score mean anything? I’m thinking this will mean I AM eligible for hormonal therapy. Do they tear someone different rly that has a lower %?Am I thinking correctly? Anyone’s have advice for me on the e-Cadherin loss. Would be helpful before I meet the surgeon tomorrow. I have Pleomorphic ILC

    · Share on FacebookShare on Twitter
  • MelissaDallas
    MelissaDallas Member Posts: 7,268
    edited June 2019

    E-Cadherin test is to determine ductal from lobular cancer. Ductal cancer does not show a loss of e-cadherin, so the absence confirms what you already know-that your cancer is lobular, not ductal..

    · Share on FacebookShare on Twitter
  • Meow13
    Meow13 Member Posts: 4,859
    edited June 2019

    yes E-cadherin was used to distinguish between idc and ilc, I had one of each, my idc showed no e-cadherin loss and about 25% tubular formation.

    · Share on FacebookShare on Twitter
  • edj3
    edj3 Member Posts: 2,076
    edited June 2019

    Forgive my ignorance, but is e-Cadherin always checked in biopsies?

    · Share on FacebookShare on Twitter
  • Meow13
    Meow13 Member Posts: 4,859
    edited June 2019

    My tumors were rated looking at e-cadherin at biopsy then a complete report was amended after mastectomy pathology. My biopsy said I had 2 ilc tumors but the pathology later said one ilc and one ductal. More tissues and the whole of the tumors were present so the mx pathology was more reliable.

    · Share on FacebookShare on Twitter
  • MelissaDallas
    MelissaDallas Member Posts: 7,268
    edited June 2019

    edj3, I think it must be, at least on any atypical findings, else the couldn’t know if you had ADH, ALH, LCIS, etc

    · Share on FacebookShare on Twitter
  • Elephant
    Elephant Member Posts: 88
    edited June 2019

    I would think that any biopsy would report on the e-cadherin. It was also on the pathology report received after my lumpectomy.

    · Share on FacebookShare on Twitter
  • Fairchild
    Fairchild Member Posts: 206
    edited June 2019

    Hey, Hv2Cutedimples, I also had pleomorphic cancer and did a lot of research on the meaning of the path report after I was diagnosed. The problem is that there are very few good studies of pleo ILC, so it's hard to know what exactly it means. There is some suggestion that it produces poorer outcomes, but the evidence is really limited for that. If you want more info, I could send you some if you PM me. Take care....

    · Share on FacebookShare on Twitter
  • Meow13
    Meow13 Member Posts: 4,859
    edited November 2019

    I think I read 95% of ILC tumors have e-cadherin loss.

    Here is what I read

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC33377...

    And 95% of ILC

    https://clincancerres.aacrjournals.org/content/24/...


    · Share on FacebookShare on Twitter
  • ShetlandPony
    ShetlandPony Member Posts: 4,924
    edited November 2019

    Dimples, good for you for diving into your pathology report and preparing for your appointments. Being an educated patient will help you do well. It is a steep learning curve, so ask away.

    E-cadherin loss defines ILC. E-cad is a protein involved in cell-cell adhesion, so it's loss explains some ILC characteristics such as single-file or sheet-like form. What does this mean for you? It means you have ILC. If you want to read up on ILC I recommend the Lobular Breast Cancer Alliance at lobularbreastcancer.org

    Regarding ER and PR, yes, early stage ILC is typically very hormone-driven, so hormonal therapy will be in your treatment plan. There is research suggesting an aromatase inhibitor is more effective than tamoxifen for at least a subset of ILC. If you are premenopausal and take an AI, you will need ovarian suppression with Lupron (or Zoladex). Your oncologist, not your surgeon, is the person to advise you about your systemic therapy.

    Your Ki-67 is not high. That is good.

    There are some clinical trials for ILC which could be to your advantage, including some you would enter before surgery. You can read about them on the LBCA web site that I noted above.

    · Share on FacebookShare on Twitter

Categories